A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Anlotinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ALTER1102
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 27 Dec 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 27 Dec 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 11 Jan 2016 New trial record